You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一品紅(300723.SZ)發佈半年報淨利潤升31.58%至1.07億元
格隆匯 08-15 16:04

格隆匯8月15日丨一品紅(300723.SZ)發佈2019年半年度報告,實現營業收入約7.73億元,同比增長0.71%;歸屬於上市公司股東的淨利潤約1.07億元,同比增長31.58%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤9842.49萬元,同比增長38.64%;基本每股收益0.67元。

2019年上半年,醫藥行業改革政策頻頻出台,國務院辦公廳印發《深化醫藥衞生體制改革2019年重點工作任務》,衞健委、醫保局相繼下發《2019年國家醫保藥品目錄調整工作方案》、《第一批國家重點監控合理用藥藥品目錄(化藥及生物藥)》等指導文件,醫藥行業整體受政策擾動明顯,內部結構將持續調整。同時,醫藥衞生體制改革已進入深水區,醫保控費力度持續加大,行業整體受政策擾動明顯。藥品方面,第一批“4+7”帶量採購落地實施順利,預期第二批帶量採購有望在2019年下半年推出,採購品種數量、協議採購量及試點城市都有望進一步擴大,預計帶量採購對醫藥行業的影響將持續。

面對複雜多變的行業政策和市場環境,公司堅持既定發展戰略,穩紮穩打,積極應對行業政策發展的新變化、新形勢,以促增長、穩效益為總要求,以市場為導向,以產品為中心,以創新拓未來,大力推進產品研發和技術創新,有條不紊地開展各項工作,取得了良好的成果。

報告期,公司自有產品實現收入5.91億元,同比增加40.73%。各區域市場更加均衡增長,報告期,廣東省內和廣東省以外市場增長呈現齊頭並進局面。主導產品穩步增長,二線品種快速增長,收入結構更加均衡。報告期,主導產品鹽酸克林黴素棕櫚酸脂分散片收入佔自有產品收入44.19%,馥感啉口服液、芩香清解口服液、參柏洗液、益氣健脾口服液、注射用乙酰谷酰胺等產品收入快速增長,自有產品收入結構趨向均衡發展。報告期,受到廣東省兩票制影響,代理產品收入同比下降47.65%。

報告期,自有產品收入規模同比增長40.73%,淨利潤貢獻佔比83.52%。報告期,公司繼續加大研發投入,投入研發金額4022.31萬元,同比增長30.15%。截止報告期末,公司專門從事研發工作人員154人,相對年初增加了39人。未來,公司將進一步完善和提升現有產品技術優勢,緊緊圍繞產品療效、質量標準提升、市場推廣等方面開展工作,確保產品品質過硬,安全可靠,療效顯著。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account